Two new studies reveal that ezogabine, a drug originally approved for epilepsy, may alleviate depression symptoms by targeting potassium channels in the brain. Researchers found that the drug improves function in reward-related brain regions like the ventral tegmental area (VTA), which is key to motivation and pleasure.